Six-month real-world amyloid PET outcomes after lecanemab: Greater amyloid reduction at the MCI stage than…

Cohort studyAlzheimer's & dementia (New York, N. Y.)· 2026

Six-month real-world amyloid PET outcomes after lecanemab: Greater amyloid reduction at the MCI stage than in dementia.

Geon Ha Kim, Hai-Jeon Yoon, Eun Hee Kim … Jee Hyang Jeong

Read paper

Neurologic ImagingCohort studyTreatmentQ1IF 11.9

Amyloid clearance during lecanemab treatment was faster in mild cognitive impairment than dementia.

Six-month real-world amyloid PET outcomes after lecanemab: Greater amyloid reduction at the MCI stage than in dementia.

Geon Ha Kim … Jee Hyang Jeong

Alzheimer's & dementia (New York, N. Y.) · 2026

Background

Evidence from routine clinical practice regarding stage-dependent responses to lecanemab remains limited.

Methods

Among 89 patients who received lecanemab, 50 individuals with baseline amyloid positivity and follow-up amyloid positron emission tomography were included in the primary amyloid positron emission tomography efficacy analysis.

n = 89 patients

Results

amyloid cleared faster with mild cognitive impairment than with dementia at treatment start

β 1.62 (95% CI 0.80 to 2.43)

null 0

0.80

2.43

CI excludes the null - significant

More results

Amyloid burden decreased substantially during follow-up.

Conversion to amyloid-negative status (full treatment-related amyloid clearance) occurred in 9 of 50 patients (18.0%) and was more frequent at the mild cognitive impairment stage ( p = 0.022).

More results

Patients treated at the mild cognitive impairment stage also showed more favorable short-term cognitive and functional trajectories than those treated at the dementia stage.

“

Conclusion

These findings support the potential value of earlier intervention with anti-amyloid therapy, although longer follow-up and controlled comparisons are needed to determine whether early biomarker changes translate into sustained clinical benefit.

Six-month real-world amyloid PET outcomes after lecanemab: Greater amyloid reduction at the MCI stage than in dementia.

Six-month real-world amyloid PET outcomes after lecanemab: Greater amyloid reduction at the MCI stage than in dementia.

Related papers